General
Preferred name
irinotecan
Synonyms
CPT 11 ()
CPT-11 ()
Irinotecan HCl Trihydrate ()
CPT-11 HCl Trihydrate ()
Topotecin ()
(+)-Irinotecan ()
Camptothecin 11 hydrochloride ()
CPT-11 hydrochloride ()
Irinotecan (HCl) ()
Irinotecan hydrochloride trihydrate ()
CPT-11(+)-Irinotecan ()
IRINOTECAN HYDROCHLORIDE ()
Irinotecan HCl ()
Irinotecan (hydrochloride) ()
Irinotecan (hydrochloride trihydrate) ()
VAL-413(free base) ()
(+)-Irinotecan (hydrochloride) ()
CPT-11 (hydrochloride) ()
VAL-413 ()
(+)-Irinotecan (hydrochloride trihydrate) ()
CPT-11 (hydrochloride trihydrate) ()
(+)-Irinotecan,CPT-11 ()
CPT-11 hydrochloride, (+)-Irinotecan hydrochloride ()
Irinotecan (CPT-11) HCl Trihydrate ()
Irinotecan (CPT-11) ()
Irinotecan hydrochlorideIrinotecanCamptosarCamptoCPT 11Camptothecin 11[1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12, 14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7] indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride (S)- ()
Irinotecan (hydrochloride hydrate) ()
Irinotecan-d10 (hydrochloride) ()
Onivyde ()
NSC-759878 ()
Irinotecan hydrochloride anhydrous ()
Irinotecan monohydrochloride trihydrate ()
Camptosar ()
Irinotecan hydrochloride component of xeliri ()
Onivyde pegylated liposomal (previously known as onivyde) ()
Irinotecan hydrochloride hydrate ()
DQ-2805 ()
U-101,440E ()
Campto ()
U-101440E ()
Irinotecan anhydrous free-base ()
Biotecan ()
NSC-728073 ()
Irinophore c ()
Irinotecan hydrochloirde ()
P&D ID
PD009733
CAS
100286-90-6
136572-09-3
97682-44-5
718612-62-5
Tags
available
prodrug
drug
nuisance
Approved by
PMDA
FDA
First approval
1996
Drug indication
Colorectal cancer
Ewing sarcoma
Neoplasm
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer[1].
PRICE 32
DESCRIPTION Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity[1].
PRICE 30
DESCRIPTION Irinotecan is a semisynthetic analogue of the natural plant alkaloid camptothecin (PubChem CID 24360) which functions as a DNA replication inhibitor by binding to topoisomerase I/DNA complexes . Camptothecin was first isolated from the bark and stem of Camptotheca acuminata, the Chinsese happy tree.
The PubChem CID linked here is the same isomer as recorded in irinotecan's INN record. (GtoPdb)
DESCRIPTION Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1].
PRICE 30
DESCRIPTION Inhibitor of E-NTPDases (Tocris Bioactive Compound Library)
DESCRIPTION DNA topoisomerase I inhibitor; antitumor (Tocriscreen Plus)
DESCRIPTION DNA topoisomerase I inhibitor; antitumor (Tocriscreen Total)
DESCRIPTION Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. (Enamine Bioactive Compounds)
DESCRIPTION Irinotecan Hydrochloride (CPT-11 hydrochloride) is the hydrochloride salt of a semisynthetic derivative of camptothecin. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent. (TargetMol Bioactive Compound Library)
DESCRIPTION Irinotecan hydrochloride trihydrate (CPT-11 HCl Trihydrate) keeps DNA from unwinding by inhibiting topoisomerase 1. (TargetMol Bioactive Compound Library)
DESCRIPTION Irinotecan (CPT-11), a derivative of camptothecin, is an inhibitor of DNA topoisomerase I (Topo I). Irinotecan has antitumor activity by preventing DNA strand reattachment through binding to the Topo I complex, resulting in double-stranded DNA breaks and cell death. (TargetMol Bioactive Compound Library)
Cell lines
67
Organisms
0
Compound Sets
41
AdooQ Bioactive Compound Library
A10479
Axon Medchem Screening Library
3370
Cayman Chemical Bioactives
14180
22566
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL3989514
CHEMBL481
ChEMBL Drugs
CHEMBL3989514
CHEMBL481
Concise Guide to Pharmacology 2017/18
6823
Concise Guide to Pharmacology 2019/20
6823
Concise Guide to Pharmacology 2021/22
6823
Concise Guide to Pharmacology 2023/24
6823
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00762
DrugBank Approved Drugs
DB00762
DrugCentral
1482
DrugCentral Approved Drugs
1482
DrugMAP
DMP6SC2
DrugMAP Approved Drugs
DMP6SC2
Enamine Bioactive Compounds
EBC-12141
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101097
Guide to Pharmacology
6823
LINCS compound set
10246-101
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL481
Mcule NIBR MoA Box Subset
MCULE-1702653278
MedChem Express Bioactive Compound Library
HY-16562A
HY-16568
HY-16562
NCATS Inxight Approved Drugs
7673326042
NIH Approved Oncology Drugs
487652
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Nuisance compounds in cellular assays
Prestwick Chemical Library
Reference compounds for characterizing cellular injury in high-content cellular morphology assays
ReFrame library
Selleckchem Bioactive Compound Library
irinotecan-hydrochloride
Irinotecan-Hcl-Trihydrate-Campto
Irinotecan-cpt-11
TargetMol Bioactive Compound Library
T0486L
T0486
T6228
The Spectrum Collection
Tocris Bioactive Compound Library
2688
Tocriscreen Plus
2688
Tocriscreen Total
External IDs
116
Properties
(calculated by RDKit )
Molecular Weight
586.28
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
7
Aromatic Ring Count
3
cLogP
4.09
TPSA
114.2
Fraction CSP3
0.52
Chiral centers
1.0
Largest ring
6.0
QED
0.36
Structural alerts
3
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Genotoxic
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Target
DNA topoisomerase I, mitochondrial
DNA topoisomerase I
TOP1, TOP1MT
Topo 1 inhibitor
Topoisomerase
Topo I
Target Type
Enzymes
MOA
Topoisomerase inhibitor
Inhibitor
DNA Topoisomerase I Inhibitors
Primary Target
DNA Topoisomerases
Member status
member
Indication
colorectal cancer
Cellular injury category
Genotoxin
Pathway
Autophagy
DNA Damage/DNA Repair
Cell Cycle/DNA Damage
Therapeutic Class
Anticancer Agents
Source data